Advertisement
A or DHR or TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Danaher Corporation (DHR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- A, DHR, and TMO operate in the life sciences and diagnostics sector, offering exposure to analytical instruments, bioprocessing, and research tools.
- Recent market activity shows A delivering a notable rebound with double-digit percentage gains over the past 30 days following earnings strength.
- DHR posted solid year-to-date returns of approximately 16%, supported by biotechnology segment growth and upcoming quarterly results.
- TMO reported steady first-quarter revenue growth of 6% and continues to execute acquisitions and capital returns.
- Relative performance reflects trade-offs in scale, with TMO holding the largest market capitalization and broadest product portfolio among the three.
- Valuation sensitivity and sector tailwinds from life sciences demand remain key factors influencing sentiment across all three stocks.
Introduction
Agilent Technologies (A), Danaher Corporation (DHR), and Thermo Fisher Scientific (TMO) represent established players in the life sciences and diagnostics industry. These stocks attract attention from investors seeking exposure to analytical instrumentation, bioprocessing, and laboratory solutions amid ongoing demand for healthcare innovation and research tools. The comparison examines recent price behavior, business positioning, and relative momentum to assist experienced traders and long-term investors evaluating sector allocation within healthcare equities.
A Overview and Recent Performance
Agilent Technologies provides analytical instruments and solutions for life sciences, diagnostics, and applied markets. In recent weeks, the stock has shown resilience following second-quarter fiscal 2026 results that featured 10% reported revenue growth and an earnings beat. Positive developments include portfolio expansions in biotherapeutic analysis columns and FDA approvals for diagnostic assays. Market sentiment has improved on these fundamentals, contributing to gains of roughly 10-14% over the past 30 days despite a more modest year-to-date return near 4.6%. Broader sector demand for precision tools has supported the recent activity.
DHR Overview and Recent Performance
Danaher Corporation operates across life sciences, diagnostics, and environmental solutions with a focus on bioprocessing and instrumentation. Recent market activity reflects steady biotechnology segment momentum, with core revenues up in the first quarter. The company maintains a regular dividend schedule and has an upcoming second-quarter earnings call scheduled for July 21, 2026. Year-to-date returns have reached approximately 16%, outperforming the broader market in that timeframe, though daily movements have shown some volatility relative to peers. Sentiment remains tied to execution in high-growth areas such as bioprocessing equipment.
TMO Overview and Recent Performance
Thermo Fisher Scientific delivers a comprehensive suite of life sciences research tools, diagnostics, and laboratory products. First-quarter 2026 results showed revenue growth of 6% alongside adjusted earnings per share increases, supported by acquisitions such as Clario and share repurchases. The stock has delivered year-to-date gains near 11.8% with a one-year return around 20%. Recent sentiment benefits from capital deployment initiatives and a raised dividend, positioning the company amid sustained demand for scientific instrumentation and clinical solutions.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section on its platform that highlights select AI trading bots optimized for prevailing market conditions. While hundreds of AI Trading Bots are available across thousands of tickers, only those demonstrating strong alignment with current trends, risk parameters, and performance metrics earn placement in this section. Available bots span varied trading styles, strategies, timeframes, and statistical profiles, with performance metrics typically ranging from modest single-digit monthly returns in conservative approaches to higher double-digit figures in more aggressive configurations. Investors can explore the full selection and suitability for individual tickers by visiting the Trending AI Robots page.
Head-to-Head Comparison
Business models differ in scope: A emphasizes analytical and measurement tools, DHR balances diversified industrial applications with strong bioprocessing exposure, and TMO offers the widest portfolio across research, diagnostics, and clinical markets. Growth drivers center on life sciences demand, with DHR and TMO benefiting from bioprocessing strength while A gains from instrument replacement cycles. Recent momentum favors A for short-term rebounds and DHR for year-to-date consistency. Risk factors include valuation multiples sensitive to interest rates and acquisition integration for all three. Sector exposure remains concentrated in healthcare, with TMO showing larger scale and potentially greater resilience in downturns. Market sentiment reflects shared tailwinds from research funding and diagnostics spending, offset by competitive pressures in instrumentation.
Tickeron AI Verdict
Tickeron’s AI models may currently assign a modestly higher probability to TMO based on its combination of consistent earnings delivery, broader revenue diversification, and solid relative positioning within the sector. Trend consistency in recent quarters and ongoing capital return programs contribute to this assessment, though outcomes remain probabilistic and dependent on broader market and earnings developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileDHR’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 2 TA indicator(s) are bullish while DHR’s TA Score has 6 bullish TA indicator(s), and TMO’s TA Score reflects 6 bullish TA indicator(s).
- A’s TA Score: 2 bullish, 5 bearish.
- DHR’s TA Score: 6 bullish, 4 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +2.75% price change this week, while DHR (@Medical Specialties) price change was +0.57% , and TMO (@Medical Specialties) price fluctuated +0.69% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.81%. For the same industry, the average monthly price growth was +11.88%, and the average quarterly price growth was +7.07%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
DHR is expected to report earnings on Jul 21, 2026.
TMO is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical Specialties (-0.81% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | DHR | TMO | |
| Capitalization | 37.9B | 141B | 196B |
| EBITDA | 1.96B | 7.08B | 11.7B |
| Gain YTD | -0.716 | -12.682 | -8.862 |
| P/E Ratio | 26.97 | 38.58 | 28.97 |
| Revenue | 7.23B | 24.8B | 45.2B |
| Total Cash | 1.81B | N/A | 1.12B |
| Total Debt | 3.36B | 18.5B | 43.2B |
A | DHR | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 10 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 82 | |
SMR RATING 1..100 | 44 | 80 | 62 | |
PRICE GROWTH RATING 1..100 | 49 | 52 | 48 | |
P/E GROWTH RATING 1..100 | 63 | 54 | 34 | |
SEASONALITY SCORE 1..100 | 85 | 19 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (8) in the Biotechnology industry is in the same range as DHR (10) in the Medical Specialties industry, and is in the same range as TMO (13) in the Medical Specialties industry. This means that A's stock grew similarly to DHR’s and similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (82) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry, and is in the same range as DHR (100) in the Medical Specialties industry. This means that TMO's stock grew similarly to A’s and similarly to DHR’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as TMO (62) in the Medical Specialties industry, and is somewhat better than the same rating for DHR (80) in the Medical Specialties industry. This means that A's stock grew similarly to TMO’s and somewhat faster than DHR’s over the last 12 months.
TMO's Price Growth Rating (48) in the Medical Specialties industry is in the same range as A (49) in the Biotechnology industry, and is in the same range as DHR (52) in the Medical Specialties industry. This means that TMO's stock grew similarly to A’s and similarly to DHR’s over the last 12 months.
TMO's P/E Growth Rating (34) in the Medical Specialties industry is in the same range as DHR (54) in the Medical Specialties industry, and is in the same range as A (63) in the Biotechnology industry. This means that TMO's stock grew similarly to DHR’s and similarly to A’s over the last 12 months.
| A | DHR | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 65% | 3 days ago 47% | 3 days ago 59% |
| Stochastic ODDS (%) | 3 days ago 64% | 3 days ago 71% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 57% | 3 days ago 66% |
| MACD ODDS (%) | 3 days ago 68% | 3 days ago 64% | 3 days ago 61% |
| TrendWeek ODDS (%) | 3 days ago 63% | 3 days ago 55% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 53% | 3 days ago 61% |
| Advances ODDS (%) | 3 days ago 60% | 3 days ago 54% | 3 days ago 61% |
| Declines ODDS (%) | 7 days ago 63% | 13 days ago 61% | 5 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 61% | 3 days ago 56% |
| Aroon ODDS (%) | N/A | 3 days ago 48% | 3 days ago 58% |
Advertisement